What is Bone Marrow Cancer?
Bone marrow cancer refers primarily to multiple myeloma, a malignant plasma cell neoplasm that accounts for 1-2% of all cancers and 10-15% of all hematological malignancies, though the term can also encompass leukemias, lymphomas, and other myeloproliferative disorders that originate in or extensively involve the bone marrow. 1, 2
Primary Bone Marrow Malignancies
Multiple myeloma is the most common primary bone marrow cancer in adults, with an incidence of 4.5-6.0 cases per 100,000 persons annually in Europe and a median age at diagnosis of 65-70 years 1, 2. This disease represents clonal proliferation of malignant plasma cells within the bone marrow that produce abnormal proteins (monoclonal proteins or M-proteins).
Disease Progression Spectrum
Almost all patients with multiple myeloma evolve through a predictable sequence 2:
- MGUS (Monoclonal Gammopathy of Undetermined Significance): A premalignant condition that progresses to myeloma at 1% per year
- Smoldering Multiple Myeloma (SMM): An intermediate stage with ≥10% clonal bone marrow plasma cells and/or serum paraprotein ≥3 g/dL, but without end-organ damage. This progresses at 10% per year for the first 5 years, then 3% per year for the next 5 years, then 1.5% per year thereafter 1, 2
- Symptomatic Multiple Myeloma: Requires ≥10% clonal plasma cells AND evidence of end-organ damage (CRAB criteria: hypercalcemia, renal insufficiency, anemia, or bone lesions) 2
Other Bone Marrow Malignancies
The term "bone marrow cancer" also encompasses 3:
- Leukemias: Malignancies of blood-forming cells
- Lymphomas: Can extensively infiltrate bone marrow
- Myeloproliferative disorders: Abnormal proliferation of bone marrow cells
- Myelodysplastic/myeloproliferative neoplasms: Rare heterogeneous malignancies with overlapping features 4
Secondary Bone Marrow Involvement
Bone marrow metastases from solid tumors (breast, lung, prostate, etc.) represent a distinct category where cancer spreads to the bone marrow rather than originating there. Disseminated tumor cells (DTCs) in bone marrow can persist after therapy and serve as a source of cancer relapse, displaying dormant, mesenchymal phenotypes that interact with the bone marrow microenvironment 5.
Clinical Significance
Malignancies growing in the bone marrow cause devastating consequences and are almost always fatal without treatment 6. For multiple myeloma specifically, despite improved outcomes with modern therapies (60% of transplant-eligible patients alive at 10 years in clinical trials), the 5-year overall survival for all patients remains 61.1%, and only 10-15% reach the expected survival of the matched general population 1. Most patients eventually relapse with disease that becomes refractory to treatment.
Key Diagnostic Features
Diagnosis requires 2:
- Detection of monoclonal protein via serum/urine electrophoresis and immunofixation
- Bone marrow aspiration/biopsy showing plasma cell infiltration with cytogenetic studies
- Skeletal survey or advanced imaging (MRI, CT) to evaluate bone lesions
- Complete blood count, serum creatinine, and calcium levels
The bone marrow microenvironment plays a critical role in disease progression, providing a niche that supports malignant cell survival, proliferation, and treatment resistance 6, 5.